# Teva Pharmaceutical Industries Limited American (TEVA) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $36.36, market value $42.4 billion.

## Valuation
- **P/E (trailing): 60.6×** (5-yr avg 23.4×, 3-yr avg 25.8×). Teva Pharmaceutical Industries Limited American trades at 60.6× trailing earnings, well above its own five-year average of 23.4×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 11.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.06**. A PEG of 0.06 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.4×**. Each dollar of revenue is priced at 2.4×.
- **Price / book: 5.5×**. The shares trade at 5.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 15.7×**. Enterprise value is 15.7× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 3.2%** (5-yr avg 5.3%). Free cash flow equals 3.2% of the market value, below its five-year average of 5.3%, so the shares are pricier on cash than usual.
- **Earnings yield: 1.7%**. The inverse of the P/E: 1.7% of the price is earned each year.

## Profitability
- **Gross margin: 52.5%**. Teva Pharmaceutical Industries Limited American keeps 52.5% of revenue after the direct cost of what it sells.
- **Operating margin: 9.3%**. 9.3% of revenue is left after running the business.
- **Net margin: 8.2%**. 8.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 17.8%**. 17.8% on shareholders' equity is solid.
- **Return on invested capital: 20.5%**. Return on all capital, debt included, is 20.5%: comfortably above what that capital costs.
- **Return on assets: 1.7%**. Each dollar of assets produces 1.7% of profit.

## Growth
- **Revenue growth (1 yr): 4.3%** (3-yr 5.0%/yr, 5-yr 0.7%/yr). Revenue grew 4.3% over the last year, against 0.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 183.4%**. Earnings per share rose 183.4%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 3.3%/yr**. Free cash flow has compounded at 3.3% a year over three years.

## Financial health
- **Debt to equity: 0.23**. Debt is 0.23 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Teva Pharmaceutical Industries Limited American holds more cash than debt.
- **Altman Z-score: 1.64**. A Z-score of 1.64 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Teva Pharmaceutical Industries Limited American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Teva Pharmaceutical Industries Limited American; the consensus is strong_buy, with an average price target of $41.60 (+14% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 96.8%** (YTD 16.5%, 3-mo 6.3%). The shares are up 96.8% over twelve months including dividends.
- **From 52-week high: -5.2%** (99.7% above the low). Trading 5% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 0.64** (volatility 40%). Beta of 0.64 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TEVA · Page: https://foliofundamentals.com/stocks/teva

Not investment advice.